HC Wainwright Begins Coverage on Evaxion Biotech A/S (NASDAQ:EVAX)

Stock analysts at HC Wainwright assumed coverage on shares of Evaxion Biotech A/S (NASDAQ:EVAXGet Free Report) in a research note issued to investors on Monday, Briefing.com reports. The firm set a “buy” rating and a $14.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 248.26% from the stock’s previous close.

Separately, LADENBURG THALM/SH SH reaffirmed a “neutral” rating on shares of Evaxion Biotech A/S in a research report on Thursday, December 21st.

Check Out Our Latest Analysis on EVAX

Evaxion Biotech A/S Trading Down 5.0 %

EVAX opened at $4.02 on Monday. The company has a debt-to-equity ratio of 3.95, a quick ratio of 2.81 and a current ratio of 2.81. Evaxion Biotech A/S has a one year low of $3.36 and a one year high of $18.50. The company has a market cap of $15.24 million and a P/E ratio of -0.42. The business’s 50-day simple moving average is $6.66 and its 200-day simple moving average is $8.06.

Evaxion Biotech A/S (NASDAQ:EVAXGet Free Report) last announced its quarterly earnings results on Tuesday, December 19th. The company reported ($2.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.90) by ($0.20). As a group, equities research analysts expect that Evaxion Biotech A/S will post -8.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP increased its stake in Evaxion Biotech A/S by 185.4% in the 1st quarter. Susquehanna International Group LLP now owns 118,722 shares of the company’s stock valued at $134,000 after purchasing an additional 77,122 shares in the last quarter. AE Wealth Management LLC purchased a new position in shares of Evaxion Biotech A/S in the third quarter valued at $41,000. Beacon Capital Management LLC raised its stake in shares of Evaxion Biotech A/S by 606.8% during the 4th quarter. Beacon Capital Management LLC now owns 48,633 shares of the company’s stock worth $33,000 after buying an additional 41,752 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in shares of Evaxion Biotech A/S during the 2nd quarter worth $38,000. 0.58% of the stock is currently owned by institutional investors and hedge funds.

Evaxion Biotech A/S Company Profile

(Get Free Report)

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers.

See Also

Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.